Ibrance Co-Standard Therapy for Breast Cancer: Not Reaching Major End

Ibrance (Palbociclib) has failed to significantly improve disease-free survival (DFS) (DFS) when it comes to treating patients with hormone receptor (HR)-positive/HER2-negative early breast cancer, Pfizer said recentlyPfizer noted that the findings were based on an analysis by the independent data monitoring committeethe study, launched in 2015, to assess whether adding Ibrance to standard therapies would improve DFS and prevent the recurrence of the diseaseThe trial included 5,796 HR-positive/HER2-negative patients with early leaching breast cancer, including patients at moderate to high risk of recurrencePfizer noted that no new safety signals were observed in patients treated with Ibrancebreast cancer is a global health problem and is the most common cancer in resource-poor and resource-poor areasBreast cancer is a kind of heterogeneous, diatosis disease, including several biological subtypesIn almost every Western country, a large part of the decline in mortality from breast cancer itself is due to the use of systemic assisted therapyAssisted chemotherapy refers to the treatment of cytotoxic chemotherapy after breast cancer surgery, which is aimed at eradicating cancer cell lesionsIn general, tumors, whether positive or progesterone receptors (PR), are treated with similar chemotherapy regimens